Key facts
- This page summarizes Onaiza Cadoret-Manier's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Jan 2024, 17:23.
Onaiza Cadoret-Manier - 02 Jan 2024 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)
- Reporting relationship
- EVP, Chf GL Pdt Str & Oper Ofc
- Issuer ticker
- IONS
- Reported as of
- 02 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jan 2024, 17:23:18 UTC
- Prior SEC filing
- 16 Jun 2023
- Next SEC filing
- 17 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- By: Patrick R. O'Neil, attorney-in-fact For: Onaiza Cadoret-Manier
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Onaiza Cadoret-Manier filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 04 Jan 2024.
Change
- Previous filing in this sequence was filed on 16 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IONS
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +43,200
- Change %
- Price
- $0.000000
- Shares after
- 43,200
- Date
- 02 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 43,200
- Exercise price
- $52.87
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.